Merck & Company Inc (MRK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $364.26B
Last updated: Nov 17, 2026 at 11:06 AM ET
Merck & Company Inc (MRK) P/E Ratio & Valuation History
Merck & Company (MRK) trades at 46.3x trailing earnings and 5.3x sales. Its P/E of 46.3x is above its 5-year median of 14.6x. Its forward P/E is 16.3x. The median P/E across 9 similar companies is 19.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 184.0% higher over the next year. Its free cash flow yield is 4.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 46.3x |
| Forward P/E | 16.3x |
| Price to sales | 5.3x |
| Price to book | 7.9x |
| EV/EBITDA | 33.1x |
| Price to FCF | 24.2x |
| EV/FCF | 27.2x |
| PEG | 3.6 |
| FCF yield | 4.1% |
Historical Medians
Against its 10-year medians, its P/E is 202.6% above 15.3x, its P/S is 15.2% above 4.6x and its P/B is 33.9% above 5.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 46.3x | 14.6x | 15.3x |
| P/S | 5.3x | 4.4x | 4.6x |
| P/B | 7.9x | 5.9x | 5.9x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 11.7x in 2025 to 72.7x in 2023. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $105.26 | 11.7x | 4.0x | 5.0x |
| 2024 | $99.48 | 13.0x | 3.9x | 5.5x |
| 2023 | $109.02 | 72.7x | 4.6x | 7.4x |
| 2022 | $110.95 | 14.8x | 4.7x | 6.1x |
| 2021 | $76.64 | 12.2x | 4.0x | 5.1x |
| 2020 | $81.80 | 13.8x | 5.0x | 8.2x |
| 2019 | $90.95 | 17.5x | 6.0x | 9.0x |
| 2018 | $76.41 | 17.6x | 4.8x | 7.5x |
| 2017 | $56.27 | 14.1x | 3.8x | 4.4x |
| 2016 | $58.87 | 15.6x | 4.1x | 4.1x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MRK
What is MRK's forward P/E ratio?
Merck & Company has a forward P/E ratio of 16.3x.
Is MRK stock overvalued?
GNG's valuation label for MRK is Overvalued. Its P/E of 46.3x compares with a median of 19.9x across 9 similar companies.
What is MRK's price to sales ratio?
Merck & Company has a price to sales ratio of 5.3x.
What is Merck & Company's average P/E ratio over 5 years?
Merck & Company's median P/E over the last 5 years is 14.6x, from 60 month-end values through Oct 2026.
What is MRK's PEG ratio?
Merck & Company has a PEG ratio of 3.6.
MRK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts